Treatment of hypercholesterolemia and hypertension in diabetics with coronary artery disease

Clinical Lipidology

Volumn 7, Issue 6, 2012, Pages 689-695

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

antihypertensive drug; blood pressure; coronary artery disease; diabetes mellitus; hypercholesterolemia; hypertension; lipid lowering drug; statin

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DYSLIPIDEMIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

EID: 84871369633     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.12.64     Document Type: Review

References (58)

1. Vokonas PS, Kannel WB. Epidemiology of coronary heart disease in the elderly. In: Cardiovascular Disease in the Elderly Patient (4th Edition). Aronow WS, Fleg JL, Rich MW (Eds). Informa Healthcare, NY, USA, 215- 241 (2008).
2. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am. J. Cardiol. 77, 864-866 (1996). (Pubitemid 26143498)
3. Stemmer EA. Diabetes mellitus and vascular disease. In: Vascular Disease in the Elderly. Aronow WS, Stemmer EA, Wilson SE (Eds). Futura, NY, USA, 199-220 (1997).
4. Gregoratos G, Leung G. Diabetes mellitus and cardiovascular disease in the elderly. In: Cardiovascular Disease in the Elderly Patient (4th Edition). Aronow WS, Fleg JL, Rich MW (Eds). Informa Healthcare, NY, USA, 179-214 (2008).
5. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234 (1998). (Pubitemid 28350165)
6. Aronow WS, Ahn C. Elderly diabetics with peripheral arterial disease and no coronary artery disease have a higher incidence of new coronary events than elderly nondiabetics with peripheral arterial disease and prior myocardial infarction treated with statins and with no lipid-lowering drug. J. Gerontol. Med. Sci. 58A, 573-575 (2003). (Pubitemid 36702697)
7. Castelli WP, Wilson PWF, Levy D, Anderson K. Cardiovascular disease in the elderly. Am. J. Cardiol. 63, H12-H19 (1989).
8. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann. Intern. Med. 115, 687-693 (1991).
9. Benfante R, Reed D. Is elevated serum cholesterol level a factor for coronary heart disease in the elderly? JAMA 263, 393-396 (1990). (Pubitemid 20026012)
10. Rubin SM, Sidney S, Black DM et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann. Intern. Med. 113, 916-920 (1990).
11. Aronow WS, Ahn C. Correlation of serum lipids with the presence or absence of coronary artery disease in 1,793 men and women aged > or = 62 years. Am. J. Cardiol. 73, 702-703 (1994).
12. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA 289, 2560-2572 (2003). (Pubitemid 37430158)
13. Aronow WS, Ahn C, Kronzon I, Koenigsberg M. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am. J. Cardiol. 67, 295-299 (1991).
14. Psaty BM, Furberg CD, Kuller LH et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch. Intern. Med. 161, 1183-1192 (2001). (Pubitemid 32691515)
15. Aronow WS, Fleg JL, Pepine CJ et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J. Am. Coll. Cardiol. 57, 2037-2114 (2011).
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
17. Pyorala K, Pedersen TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20, 614-620 (1997). (Pubitemid 27143424)
18. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med. 335, 1001-1009 (1996). (Pubitemid 26338729)
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group. N. Engl. J. Med. 339, 1349-1357 (1998).
20. Calhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes mellitus in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364, 685-696 (2004). (Pubitemid 39140624)
21. Aronow WS, Ahn C, Gutstein H. Reduction of new coronary events and of new atherothrombotic brain infarction in older persons with diabetes mellitus, prior myocardial infarction, and serum low-density lipoprotein cholesterol >/=125 mg/dl treated with statins. J. Gerontol. Med. Sci. 57A, M747-M750 (2002). (Pubitemid 35340556)
22. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am. J. Cardiol. 89, 67-69 (2002). (Pubitemid 34066591)
23. Aronow WS, Ahn C, Gutstein H. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol >or=125 mg/dl treated with statins versus no lipid-lowering drug. J. Gerontol. Med. Sci. 57A, M333-M335 (2002). (Pubitemid 34464975)
24. Cholesterol Treatment Triaists' Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117-125 (2008).
25. ACCORD Study Group, Ginsberg HN, Elam MB. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
26. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): a randomised controlled trial. Lancet 366, 1849-1861 (2005).
27. Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias-time for a reassessment. N. Engl. J. Med. 365, 481-484 (2011).
28. AIM-High Investigators, Boden WE, Probstfield JL et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011).
29. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004). (Pubitemid 38924592)
30. Brunzell JD, Daviodson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk. Consensus Conference Report from the American Diabetes Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol. 51, 1512-1524 (2008). (Pubitemid 351470037)
31. Smith SC Jr, Benjamin EJ, Bonow RO et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J. Am. Coll. Cardiol. 58, 2432-2446 (2011).
32. Ghosh S, Aronow WS. Utilization of lipid-lowering drugs in elderly persons with increased serum low-density lipoprotein cholesterol associated with coronary artery disease, symptomatic peripheral arterial disease, prior stroke, or diabetes mellitus before and after an educational program on dyslipidemia treatment. J. Gerontol. Med. Sci. 58A, 432-435 (2003). (Pubitemid 36535113)
33. Varma R, Aronow WS, Gandelman G, Zammit C. Prevalence of adequate control of increased serum low-density lipoprotein cholesterol in self-pay or Medicare patients versus Medicaid or private insurance patients followed in a university general medicine clinic. Am. J. Cardiol. 95, 269-270 (2005). (Pubitemid 40092099)
34. Gandelman G, Aronow WS, Varma R. Prevalence of adequate blood pressure control in self-pay or Medicare patients versus Medicaid or private insurance patients with systemic hypertension followed in a university cardiology or general medicine clinic. Am. J. Cardiol. 94, 815-816 (2004). (Pubitemid 39221512)
35. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 26(Suppl. 1), S33- S50 (2003).
36. Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Press. Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115, 2761-2788 (2007).
37. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N. Eng. J. Med. 358, 1887-1898 (2008). (Pubitemid 351620109)
38. Aronow WS. Hypertension guidelines. Hypertension 58, 347-348 (2011).
39. Banach M, Michalska M, Kjeldsen SE et al. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist? Expert Opin Pharmacother. 12, 1835-1844 (2011).
40. Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol. Arch. Med. Wewn. 121, 253-258 (2011).
41. Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press. 21, 3-5 (2012).
42. Aronow WS. Ten key points from the American College of Cardiology Foundation/American Heart Association 2011 expert consensus document on hypertension in the elderly. Am. J. Ther. doi:10.1097/MJT.0b013e3182217894 (2011) (Epub ahead of print).
43. Banach M, Aronow WS. Hypertension therapy in the elderly - do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J. Hum. Hypertens. 26(11), 641-643 (2012).
44. Bangalore S, Qin J, Sloan S et al. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction (PROVE IT-TIMI) 22 trial. Circulation 122, 2142-2151 (2010).
45. Cooper-DeHoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304, 61-68 (2010).
46. ACCORD Study Group, Cushman WC, Evans GW et al. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
47. Nilsson PM. ACCORD and risk-factor control in Type 2 diabetes. N. Engl. J. Med. 362, 1628-1630 (2010).
48. Mancia G, Schumacher H, Redon J et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation 124, 1727-1736 (2011).
49. Redon J, Mancia G, Sleight P et al. Safety and efficacy of low blood pressures among patients with diabetes. Subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J. Am. Coll. Cardiol. 59, 74-83 (2012).
50. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS38. UK Prospective Diabetes Study Group. BMJ 317, 703-713 (1998).
51. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intense blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351, 1755-1762 (1998). (Pubitemid 28269185)
52. Patel A, ADVANCE Collaborative Group, MacMahon S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829-840 (2007). (Pubitemid 47362321)
53. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann. Intern. Med. 154, 541-548 (2011).
54. Ovbiagele B, Diener HC, Yusuf S et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 306, 2137-2144 (2011).
55. Banach M, Bhatia V, Feller MA et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am. J. Cardiol. 107, 1208-1214 (2011).
56. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am. J. Cardiol. 89, 1207-1209 (2002). (Pubitemid 34475103)
57. Aronow WS. Current role of beta blockers in the treatment of hypertension. Expert Opin Pharmacother. 11, 2599-2607 (2010).
58. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000). (Pubitemid 30051645)